Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
TuHURA Biosciences ( (HURA) ) just unveiled an update.
In a significant merger, TuHURA Biosciences has joined forces with Kintara Therapeutics, aiming to revolutionize cancer immunotherapy by tackling resistance issues. The newly combined entity, trading under ‘HURA’ on Nasdaq, plans to launch a pivotal Phase 3 trial in 2025 focused on Merkel Cell Carcinoma. With a $31 million funding secured, TuHURA aims to advance its innovative technologies, potentially unlocking new avenues in oncology treatments and creating substantial value for investors.
For detailed information about HURA stock, go to TipRanks’ Stock Analysis page.
